Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 2/20 | 0.46 |
| ▸ | EGLN2 | Q96KS0 | 12/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.37 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30841993 | 0.78 | CYP2A6 (0.45) | EGLN2 | |
| SCHEMBL30842043 | 0.75 | DRD2 (0.42) | EGLN2KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL30842018 | 0.75 | DYRK1A (0.37) | EGLN2KDM4ECLK4 | |
| SCHEMBL30841994 | 0.72 | EGLN2 (0.33) | EGLN2ALDH1A1 | |
| SCHEMBL16252838 | 0.69 | ALDH1A1 (0.42) | EGLN2KDM4EALDH1A1HPGDCLK4 | |
| SCHEMBL30842096 | 0.69 | HRH3 (0.40) | EGLN2CLK4 | |
| SCHEMBL31030490 | 0.69 | HPGD (0.42) | KDM4EALDH1A1HPGDSMN1; SMN2GLA | |
| SCHEMBL20906374 | 0.68 | CYP11B2 (0.44) | CYP11B2CYP11B1 | |
| SCHEMBL3162634 | 0.67 | KDM4E (0.72) | CYP11B2EGLN2KDM4EALDH1A1HPGD | |
| SCHEMBL3292911 | 0.66 | CNR2 (0.57) | CYP11B2CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260085045-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO LTD (CN) | 2026-03-26 | — | — | US | disclosed |
| US-12497366-B2 | Nitrogen-containing heterocyclic derivative inhibitor, preparation method therefor and use thereof | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2025-12-16 | — | — | US | disclosed |
| US-20250326722-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO LTD (CN) | 2025-10-23 | — | — | US | disclosed |
| EP-4588914-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2025-07-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260085045-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | NPR1, CBR1, NAT1 | CYP11B2 27/4885EGLN2 1446/4885KDM4E 4842/4885 |
| US-12497366-B2 | Nitrogen-containing heterocyclic derivative inhibitor, preparation method therefor and use thereof | WEE1, WEE2, NOS1 | CYP11B2 30/4885EGLN2 162/4885KDM4E 3281/4885 |
| US-20250326722-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | WEE1, WEE2, NOS1 | CYP11B2 30/4885EGLN2 162/4885KDM4E 3281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.